MAPT and Alzheimer disease: Among miRNAs dysregulated in AD and PD (Table 1 and Table 3, Figure 1), miR-132 showed promising therapeutic properties in AD mouse models, where treatment with miR-132 mimics restores memory function [79] and reduces phosphorylation of tau and Aβ [72,73].